[시장보고서]세계의 전임상 CRO 시장 : 시장 규모, 점유율 및 동향 분석(서비스별, 모델 유형별, 최종 용도별, 지역별), 부문별 예측(2025-2033년)

세계의 전임상 CRO 시장 : 시장 규모, 점유율 및 동향 분석(서비스별, 모델 유형별, 최종 용도별, 지역별), 부문별 예측(2025-2033년)

Preclinical CRO Market Size, Share & Trends Analysis Report By Service (Toxicology Testing, Bioanalysis & DMPK Studies, Chemistry), By Model Type, By End-use, By Region, And Segment Forecasts, 2025 - 2033

상품코드 : 1842391

리서치사 : Grand View Research

발행일 : 2025년 09월

페이지 정보 : 영문 150 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,861,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,350,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 13,329,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

전임상 CRO 시장 요약

세계의 전임상 CRO 시장 규모는 2024년에 61억 9,000만 달러로 평가되었고, 2033년에는 123억 7,000만 달러에 이를 것으로 예측되며, 2025-2033년 연평균 복합 성장률(CAGR)은 8.03%로 성장합니다.시장은 연구개발 투자 급증, 의약품 개발 복잡화, 전문적 한편 첨단치료법에 수요 시프트를 원동력으로 하고 있습니다.

이 시장의 주요 원동력은 신약개발의 복잡성 증가와 더불어 사내 연구 인프라에 소요되는 높은 비용으로 인해 전임상 CRO 서비스 도입이 확대되고 있습니다. 의약품 개발 기업은 독성학, 약리학, 생물학적 분석 등의 연구를 전문 서비스 제공업체에 아웃소싱하여 시장 출시 시간을 단축하고 운영 리스크를 관리하고 있습니다. 이러한 추세는 보다 광범위한 전임상 평가가 필요한 만성질환 및 복합질환의 확산으로 인해 더욱 가속화되고 있습니다. 아웃소싱을 통해 자원이 한정된 소규모 생명공학 기업들은 대규모 사내 조직 없이도 첨단 기술 및 세계 전문 지식을 활용할 수 있습니다.

부문 대시보드
세계의 전임상 CRO 시장 : 변동 분석, 서비스별
세계의 전임상 CRO 시장 규모와 동향 분석 : 서비스별(2021-2033년)
바이오 어널리시스 및 DMPK 연구
- 생체외 ADME
- 생체내 PK
독성 시험
- GLP
- 비GLP
화합물 관리
- 프로세스 연구개발
- 커스텀 합성
- 기타
화학
- 의약화학
- 계산 화학
안전성 약리학
기타

제5장 전임상 CRO 시장 : 모델 유형별 추정, 동향 분석

부문 대시보드
세계의 전임상 CRO 시장 : 변동 분석, 모델 유형별
세계의 전임상 CRO 시장 규모와 동향 분석 : 모델 유형별(2021-2033년)
환자 유래 오가노이드(PDO) 모델
환자 유래 이종 이식(PDX) 모델

제6장 전임상 CRO 시장 : 최종 용도별 추정, 동향 분석

부문 대시보드
세계의 전임상 CRO 시장 : 변동 분석, 최종 용도별
세계의 전임상 CRO 시장 규모와 동향 분석 : 최종 용도별(2021-2033년)
바이오의약품 기업
정부기관 및 학술기관
의료기기 기업

제7장 전임상 CRO 시장 : 지역별 추정, 동향 분석(서비스별, 모델 유형별, 최종 용도별)

시장 대시보드 : 지역별
세계 시장 스냅숏 : 지역별
시장 규모 예측과 동향 분석(2021-2033년)
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트
- 오만
- 카타르

제8장 경쟁 구도

기업 분류
전임상 CRO 시장 점유율 분석(2024년)
기업 개요
- Eurofins Scientific
- PRA Health Sciences, Inc.
- Wuxi AppTec
- Medpace, Inc.
- Charles River Laboratories International, Inc.
- PPD Thermo Fisher Scientific, Inc.
- SGA SA
- Intertek Group Plc(IGP)
- LABCORP
- Crown Bioscience

LSH

영문 목차

영문목차

Preclinical CRO Market Summary

The global preclinical CRO market size was estimated at USD 6.19 billion in 2024 and is projected to reach USD 12.37 billion by 2033, growing at a CAGR of 8.03% from 2025 to 2033. The market is driven escalating R&D investments, the growing complexity of drug development, and the shifting demand toward specialized and advanced therapeutic modalities.

The market is primarily driven by the increasing complexity of drug discovery, along with the high costs of in-house research infrastructure, is driving greater adoption of preclinical CRO services. Drug developers are outsourcing studies such as toxicology, pharmacology, and bioanalysis to specialized service providers to reduce time-to-market and manage operational risks. This trend is further amplified by the growing prevalence of chronic and complex diseases, which require more extensive preclinical evaluations. Outsourcing also enables smaller biotech firms, which often have limited resources, to access advanced technologies and global expertise without the need for large-scale internal setups.

Global Preclinical CRO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global preclinical CRO market report based on service, model type, end-use, and region:

Service Outlook (Revenue, USD Million, 2021 - 2033)
Bioanalysis and DMPK studies
- In vitro ADME
- In-vivo PK
Toxicology Testing
- GLP
- Non-GLP
Compound Management
- Process R&D
- Custom Synthesis
- Others
Chemistry
- Medicinal Chemistry
- Computation Chemistry
Safety Pharmacology
Others
Model Type Outlook (Revenue, USD Million, 2021 - 2033)
Patient Derived Organoid (PDO) Model
Patient derived xenograft model
End-use Outlook (Revenue, USD Million, 2021 - 2033)
Biopharmaceutical Companies
Government and Academic Institutes
Medical Device Companies
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Norway
- Sweden
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
Latin America
- Brazil
- Argentina
Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
- Oman
- Qatar

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Value chain based analysis (Model 2)
- 1.7.3. Multivariate Analysis (Model 3)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Preclinical CRO Market: Variables, Trends, & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Ancillary Market Outlook
3.2. Preclinical CRO Market Dynamics
- 3.2.1. Market Driver Impact Analysis
- 3.2.2. Market Restraint Analysis
3.3. Technological Landscape
3.4. Pricing Model Analysis
3.5. Preclinical CRO Market: Analysis Tools
- 3.5.1. Porter's Five Forces Analysis
- 3.5.2. PESTEL Analysis

Chapter 4. Preclinical CRO Market: Service Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Global Preclinical CRO Market Service Movement Analysis
4.3. Global Preclinical CRO Market Size & Trend Analysis, by Service, 2021 to 2033 (USD Million)
4.4. Bioanalysis and DMPK Studies
- 4.4.1. Bioanalysis and DMPK Studies Market Estimates and Forecasts, 2021 - 2033 (USD million)
- 4.4.2. In vitro ADME
  - 4.4.2.1. In vitro ADME Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.3. In-vivo PK
  - 4.4.3.1. In-vivo PK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Toxicology Testing
- 4.5.1. Toxicology Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5.2. GLP
  - 4.5.2.1. GLP Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5.3. Non-GLP
  - 4.5.3.1. Non-GLP Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Compound Management
- 4.6.1. Compound Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6.2. Process R&D
  - 4.6.2.1. Process R&D Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6.3. Custom Synthesis
  - 4.6.3.1. Custom Synthesis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6.4. Others
  - 4.6.4.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.7. Chemistry
- 4.7.1. Chemistry Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.7.2. Medicinal Chemistry
  - 4.7.2.1. Medicinal Chemistry Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.7.3. Computation Chemistry
  - 4.7.3.1. Computation Chemistry Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.8. Safety Pharmacology
- 4.8.1. Safety Pharmacology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.9. Others
- 4.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Preclinical CRO Market: Model Type Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Global Preclinical CRO Market Model type Movement Analysis
5.3. Global Preclinical CRO Market Size & Trend Analysis, by Model type, 2021 to 2033 (USD Million)
5.4. Patient Derived Organoid (PDOs) Models
- 5.4.1. Patient Derived Organoid (PDOs) Models Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Patient Derived Xenograft (PDX) Models
- 5.5.1. Patient Derived Xenograft (PDX) Models Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Preclinical CRO Market: End Use Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Global Preclinical CRO Market End Use Movement Analysis
6.3. Global Preclinical CRO Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
6.4. Biopharmaceutical Companies
- 6.4.1. Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Government and Academic Institutes
- 6.5.1. Government and Academic Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Medical Device Companies
- 6.6.1. Medical Device Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Preclinical CRO Market: Regional Estimates & Trend Analysis by Service, Model Type, End Use

7.1. Regional Market Dashboard
7.2. Global Regional Market Snapshot
7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
7.4. North America
- 7.4.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.2. U.S.
  - 7.4.2.1. Key Country Dynamics
  - 7.4.2.2. Competitive Scenario
  - 7.4.2.3. Regulatory Framework
  - 7.4.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Canada
  - 7.4.3.1. Key Country Dynamics
  - 7.4.3.2. Competitive Scenario
  - 7.4.3.3. Regulatory Framework
  - 7.4.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.4. Mexico
  - 7.4.4.1. Key Country Dynamics
  - 7.4.4.2. Competitive Scenario
  - 7.4.4.3. Regulatory Framework
  - 7.4.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Europe
- 7.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.2. UK
  - 7.5.2.1. Key Country Dynamics
  - 7.5.2.2. Competitive Scenario
  - 7.5.2.3. Regulatory Framework
  - 7.5.2.4. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.3. Germany
  - 7.5.3.1. Key Country Dynamics
  - 7.5.3.2. Competitive Scenario
  - 7.5.3.3. Regulatory Framework
  - 7.5.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.4. France
  - 7.5.4.1. Key Country Dynamics
  - 7.5.4.2. Competitive Scenario
  - 7.5.4.3. Regulatory Framework
  - 7.5.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.5. Italy
  - 7.5.5.1. Key Country Dynamics
  - 7.5.5.2. Competitive Scenario
  - 7.5.5.3. Regulatory Framework
  - 7.5.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.6. Spain
  - 7.5.6.1. Key Country Dynamics
  - 7.5.6.2. Competitive Scenario
  - 7.5.6.3. Regulatory Framework
  - 7.5.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.7. Denmark
  - 7.5.7.1. Key Country Dynamics
  - 7.5.7.2. Competitive Scenario
  - 7.5.7.3. Regulatory Framework
  - 7.5.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.8. Sweden
  - 7.5.8.1. Key Country Dynamics
  - 7.5.8.2. Competitive Scenario
  - 7.5.8.3. Regulatory Framework
  - 7.5.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.9. Norway
  - 7.5.9.1. Key Country Dynamics
  - 7.5.9.2. Competitive Scenario
  - 7.5.9.3. Regulatory Framework
  - 7.5.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Asia Pacific
- 7.6.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.2. Japan
  - 7.6.2.1. Key Country Dynamics
  - 7.6.2.2. Competitive Scenario
  - 7.6.2.3. Regulatory Framework
  - 7.6.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.3. China
  - 7.6.3.1. Key Country Dynamics
  - 7.6.3.2. Competitive Scenario
  - 7.6.3.3. Regulatory Framework
  - 7.6.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.4. India
  - 7.6.4.1. Key Country Dynamics
  - 7.6.4.2. Competitive Scenario
  - 7.6.4.3. Regulatory Framework
  - 7.6.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.5. Australia
  - 7.6.5.1. Key Country Dynamics
  - 7.6.5.2. Competitive Scenario
  - 7.6.5.3. Regulatory Framework
  - 7.6.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.6. South Korea
  - 7.6.6.1. Key Country Dynamics
  - 7.6.6.2. Competitive Scenario
  - 7.6.6.3. Regulatory Framework
  - 7.6.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.7. Thailand
  - 7.6.7.1. Key Country Dynamics
  - 7.6.7.2. Competitive Scenario
  - 7.6.7.3. Regulatory Framework
  - 7.6.7.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7. Latin America
- 7.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.2. Brazil
  - 7.7.2.1. Key Country Dynamics
  - 7.7.2.2. Competitive Scenario
  - 7.7.2.3. Regulatory Framework
  - 7.7.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.3. Argentina
  - 7.7.3.1. Key Country Dynamics
  - 7.7.3.2. Competitive Scenario
  - 7.7.3.3. Regulatory Framework
  - 7.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8. MEA
- 7.8.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.2. South Africa
  - 7.8.2.1. Key Country Dynamics
  - 7.8.2.2. Competitive Scenario
  - 7.8.2.3. Regulatory Framework
  - 7.8.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.3. Saudi Arabia
  - 7.8.3.1. Key Country Dynamics
  - 7.8.3.2. Competitive Scenario
  - 7.8.3.3. Regulatory Framework
  - 7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.4. UAE
  - 7.8.4.1. Key Country Dynamics
  - 7.8.4.2. Competitive Scenario
  - 7.8.4.3. Regulatory Framework
  - 7.8.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.5. Kuwait
  - 7.8.5.1. Key Country Dynamics
  - 7.8.5.2. Competitive Scenario
  - 7.8.5.3. Regulatory Framework
  - 7.8.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.6. Oman
  - 7.8.6.1. Key Country Dynamics
  - 7.8.6.2. Competitive Scenario
  - 7.8.6.3. Regulatory Framework
  - 7.8.6.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.7. Qatar
  - 7.8.7.1. Key Country Dynamics
  - 7.8.7.2. Competitive Scenario
  - 7.8.7.3. Regulatory Framework
  - 7.8.7.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

8.1. Company Categorization
8.2. Preclinical CRO Market Share Analysis, 2024
8.3. Company Profiles
- 8.3.1. Eurofins Scientific
  - 8.3.1.1. Company overview
  - 8.3.1.2. Financial performance
  - 8.3.1.3. Product benchmarking
  - 8.3.1.4. Strategic initiatives
- 8.3.2. PRA Health Sciences, Inc.
  - 8.3.2.1. Company overview
  - 8.3.2.2. Financial performance
  - 8.3.2.3. Product benchmarking
  - 8.3.2.4. Strategic initiatives
- 8.3.3. Wuxi AppTec
  - 8.3.3.1. Company overview
  - 8.3.3.2. Financial performance
  - 8.3.3.3. Product benchmarking
  - 8.3.3.4. Strategic initiatives
- 8.3.4. Medpace, Inc.
  - 8.3.4.1. Company overview
  - 8.3.4.2. Financial performance
  - 8.3.4.3. Product benchmarking
  - 8.3.4.4. Strategic initiatives
- 8.3.5. Charles River Laboratories International, Inc.
  - 8.3.5.1. Company overview
  - 8.3.5.2. Financial performance
  - 8.3.5.3. Product benchmarking
  - 8.3.5.4. Strategic initiatives
- 8.3.6. PPD Thermo Fisher Scientific, Inc.
  - 8.3.6.1. Company overview
  - 8.3.6.2. Financial performance
  - 8.3.6.3. Product benchmarking
  - 8.3.6.4. Strategic initiatives
- 8.3.7. SGA SA
  - 8.3.7.1. Company overview
  - 8.3.7.2. Financial performance
  - 8.3.7.3. Product benchmarking
  - 8.3.7.4. Strategic initiatives
- 8.3.8. Intertek Group Plc (IGP)
  - 8.3.8.1. Company overview
  - 8.3.8.2. Financial performance
  - 8.3.8.3. Product benchmarking
  - 8.3.8.4. Strategic initiatives
- 8.3.9. LABCORP
  - 8.3.9.1. Company overview
  - 8.3.9.2. Financial performance
  - 8.3.9.3. Product benchmarking
  - 8.3.9.4. Strategic initiatives
- 8.3.10. Crown Bioscience
  - 8.3.10.1. Company overview
  - 8.3.10.2. Financial performance
  - 8.3.10.3. Product benchmarking
  - 8.3.10.4. Strategic initiatives